In this section, you will find new information and key facts on various aspects of Canada’s research-based pharmaceutical industry.
A new KPMG study shows that research and development investments made by Canada’s innovative pharmaceutical sector continue to be chronically under-reported by the Government of Canada at an increasing amount year-over-year.
The Summary of 2013 R&D Spending and Investments by Rx&D Members is the fourth annual report commissioned by Canada’s Research-Based Pharmaceutical Companies (Rx&D) that shows an alarming disparity between what the government reports and the more than $1 billion that the industry actually invests annually. For 2013, KPMG estimates 46% of the industry’s R&D investment will be overlooked by the Patented Medicine Prices Review Board (PMPRB) meaning that the official report published by the Government of Canada will be far from a true reflection of the industry’s contribution to Canada.
One of the most rigorous and detailed forecasts ever conducted for the Canadian private drug plan market shows that drug cost growth within private plans will be in the low single digit range in the coming 5-year period. This news is important for Canadian employers who offer drug coverage to their employees as part of their health benefit plans. These results show that, at a market level, the private drug plan system growth will be sustainable.
Rx&D commissioned IMS Brogan, the Canadian business unit of IMS Health a global leader in healthcare market insights, to conduct a forecast of private drug plan drug costs for 2013-2017. The IMS Brogan Private Drug Plan Drug Forecast shows that the Compounded Annual Growth Rate (CAGR) of private market drug costs, at an overall market level, will be in the range of 1.6% to 2.8 % over the five-year forecast period.
This is the sixth edition of IRAM, an annual study published by Canada’s Research-Based Pharmaceutical Companies (Rx&D). IRAM’s priority objective is to explore how the public reimbursement of innovative medicines in Canada compares to that found in other member countries of the Organization for Economic Cooperation and Development (OECD ).
The study produces a ranking of OECD nations that compares how well Canadian public drug plans reimburse various drug and certain disease categories versus the average of the rest of the OECD nations. This edition reviews 204 drugs representing 257 indications, the most ever reported, and covers 32 countries in the OECD .